Exforge Hct

See Contraindications. Concomitant renin-angiotensin system (RAS) inhibitors, K⁺ supplements, K⁺ sparing diuretics, K⁺-containing salt substitutes or other drugs (eg, heparin) may cause hyperkalemia and, in heart failure patients to increases in serum creatinine. Potentiates simvastatin (limit simvastatin dose to 20mg daily), cyclosporine, or tacrolimus (monitor levels). May be potentiated by CYP3A4 inhibitors. Monitor BP if coadministered with CYP3A4 inducers (eg, rifampicin, St. Johns wort). Monitor for hypotension with concomitant sildenafil. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). Adjust antidiabetic, antigout medications. May increase lithium levels; monitor. Carbamazepine may lead to symptomatic hyponatremia. Cyclosporine may increase the risk of hyperuricemia and gout-type complications. Dual inhibition of the RAS with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely; in general, avoid combined use of RAS inhibitors. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Give at least 4hrs before or 4–6hrs after administration of ion exchange resins (eg, cholestyramine, colestipol). May interfere with parathyroid tests.